Natural and synthetic polymer-based smart biomaterials for management of ulcerative colitis: a review of recent developments and future prospects

  • Muhammad Sohail
  • Mudassir
  • Muhammad Usman Minhas
  • Shahzeb Khan
  • Zahid Hussain
  • Marcel de Matas
  • Syed Ahmed Shah
  • Samiullah Khan
  • Mubeen Kousar
  • Kaleem Ullah
Review Article

Abstract

Ulcerative colitis (UC) is an inflammatory disease of the colon that severely affects the quality of life of patients and usually responds well to anti-inflammatory agents for symptomatic relief; however, many patients need colectomy, a surgical procedure to remove whole or part of the colon. Though various types of pharmacological agents have been employed for the management of UC, the lack of effectiveness is usually predisposed to various reasons including lack of target-specific delivery of drugs and insufficient drug accumulation at the target site. To overcome these glitches, many researchers have designed and characterized various types of versatile polymeric biomaterials to achieve target-specific delivery of drugs via oral route to optimize their targeting efficiency to the colon, to improve drug accumulation at the target site, as well as to ameliorate off-target effects of chemotherapy. Therefore, the aim of this review was to summarize and critically discuss the pharmaceutical significance and therapeutic feasibility of a wide range of natural and synthetic biomaterials for efficient drug targeting to colon and rationalized treatment of UC. Among various types of biomaterials, natural and synthetic polymer-based hydrogels have shown promising targeting potential due to their innate pH responsiveness, sustained and controlled release characteristics, and microbial degradation in the colon to release the encapsulated drug moieties. These characteristic features make natural and synthetic polymer-based hydrogels superior to conventional pharmacological strategies for the management of UC.

Keywords

Ulcerative colitis Biomaterials Hydrogels Biomedical applications Ulcerative colitis 

Notes

Acknowledgements

The authors would like to acknowledge the Higher Education Commission of Pakistan for the financial support through Project No. 21-487/SRGP/R&D/HEC/2015. This study became possible due to the support of the Higher Education Commission of Pakistan.

Compliance with ethical standards

Conflict of interest

The authors reported that they have no conflict of interest in the present research work.

References

  1. 1.
    Danese S, Fiocchi C. Ulcerative colitis. N. Engl. J. Med. 2011;365:1713–25.  https://doi.org/10.1055/s-0030-1268248.CrossRefPubMedGoogle Scholar
  2. 2.
    Cosnes J, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. YGAST. 2011;140:1785–1794.e4.  https://doi.org/10.1053/j.gastro.2011.01.055.Google Scholar
  3. 3.
    B. Moum, A. Ekbom, M.H. Vatn, K. Elgjo, Change in the extent of colonoscopic and histological involvement in ulcerative colitis over time, 94 (1999) 0–5.Google Scholar
  4. 4.
    E. Langholz, Current trends in inflammatory bowel disease: the natural history, (2010) 77–86. doi: https://doi.org/10.1177/1756283X10361304, 3
  5. 5.
    M. Van Der Have, H.H. Fidder, M. Leenders, A.A. Kaptein, M.E. Van Der Valk, A.A. Van Bodegraven, G. Dijkstra, D.J. De Jong, M. Pierik, C.Y. Ponsioen, A.E.V.D.M. Jong, C.J. Van Der Woude, P.C. Van De Meeberg, M.J.L. Romberg-camps, J.R. Vermeijden, P.D. Siersema, B. Oldenburg, Self-reported disability in patients with inflammatory bowel disease largely determined by disease activity and illness perceptions, 21 (2015) 369–377. doi: https://doi.org/10.1097/MIB.0000000000000278.
  6. 6.
    L. Zhao, J. Li, T. Yu, G. Chen, Y. Yuan, Q. Chen, 5-Aminosalicylates reduce the risk of colorectal neoplasia in patients with ulcerative colitis: an updated meta-analysis, 9 (2014). doi: https://doi.org/10.1371/journal.pone.0094208.
  7. 7.
    Xu J, Tam M, Samadei S, Lerouge S, Barralet J, Stevenson M, et al. Department of Mining and Materials Engineering, Faculty of Engineering, McGill Marta Cerruti, PhDMucoadhesive chitosan hydrogels as rectal drug delivery vessels to treat ulcerative colitis. Acta Biomater. 2016;  https://doi.org/10.1016/j.actbio.2016.10.026.
  8. 8.
    Duan H, Lü S, Gao C, Bai X, Qin H, Wei Y, et al. Mucoadhesive microparticulates based on polysaccharide for target dual drug delivery of 5-aminosalicylic acid and curcumin to inflamed colon. Colloids Surfaces B Biointerfaces. 2016;145:510–9.  https://doi.org/10.1016/j.colsurfb.2016.05.038.CrossRefPubMedGoogle Scholar
  9. 9.
    Sales-Campos H, Basso PJ, Alves VBF, Fonseca MTC, Bonfá G, Nardini V, et al. Classical and recent advances in the treatment of inflammatory bowel diseases. Braz J Med Biol Res. 2015;48:96–107.  https://doi.org/10.1590/1414-431X20143774.CrossRefPubMedGoogle Scholar
  10. 10.
    Xu J, Tam M, Samaei S, Lerouge S, Barralet J, Stevenson MM, et al. Mucoadhesive chitosan hydrogels as rectal drug delivery vessels to treat ulcerative colitis. Acta Biomater. 2017;48:247–57.  https://doi.org/10.1016/j.actbio.2016.10.026.CrossRefPubMedGoogle Scholar
  11. 11.
    Panccione R, Ghosh S, Middleton S, Marquez JR, Khalif I, Flint L, et al. Infliximab, azathioprine, or infliximab+ azathioprine for treatment of moderate to severe ulcerative colitis: the UC SUCCESS trial. Gastroenterology. 2011;140:S-134.Google Scholar
  12. 12.
    Cottone M, Kohn A, Daperno M, Armuzzi A, Guidi L, D’Inca R, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:30–5.  https://doi.org/10.1016/j.cgh.2010.09.026.CrossRefPubMedGoogle Scholar
  13. 13.
    Smits P, Thien T, Erkelens DW, Romijn JA. The Netherlands Journal of Medicine. 2004;Google Scholar
  14. 14.
    ASHP. No title. In: AHFS; 1994.Google Scholar
  15. 15.
    Gisbert JP, Chaparro M. Systematic review with meta-analysis: inflammatory bowel disease in the elderly. Aliment Pharmacol Ther. 2014;39:459–77.  https://doi.org/10.1111/apt.12616.CrossRefPubMedGoogle Scholar
  16. 16.
    Ahmed O, Nguyen GC. Therapeutic challenges of managing inflammatory bowel disease in the elderly patient. Expert Rev. Gastroenterol. Hepatol. 2016;10:1005–10.  https://doi.org/10.1080/17474124.2016.1179579.CrossRefPubMedGoogle Scholar
  17. 17.
    Shilpa, Srinivasan BP, Chauhan M. Niosomes as vesicular carriers for delivery of proteins and biologicals. Int. J. Drug Deliv. 2011;3:14–24.  https://doi.org/10.5138/ijdd.2010.0975.0215.03050.CrossRefGoogle Scholar
  18. 18.
    Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65:36–48.  https://doi.org/10.1016/j.addr.2012.09.037.CrossRefPubMedGoogle Scholar
  19. 19.
    Çağdaş M, Sezer AD, Bucak S. Liposomes as potential drug carrier systems for drug delivery. Nanotechnol. Nanomater. “Application Nanotechnol. Drug Deliv.”. 2014:1–50.  https://doi.org/10.5772/57028.
  20. 20.
    Aleksovski A, Dreu R, Gašperlin M, Planinšek O. Mini-tablets: a contemporary system for oral drug delivery in targeted patient groups. Expert Opin Drug Deliv. 2015;12:65–84.  https://doi.org/10.1517/17425247.2014.951633.CrossRefPubMedGoogle Scholar
  21. 21.
    Dash TR, Verma P. Matrix tablets: an approach towards oral extended release drug delivery. Int J Pharma Res Rev. 2013;2:12–24.Google Scholar
  22. 22.
    Fox CB, Kim J, Le LV, Nemeth CL, Chirra HD, Desai TA. Micro/nanofabricated platforms for oral drug delivery. J Control Release. 2015;219:431–44.  https://doi.org/10.1016/j.jconrel.2015.07.033.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Luo Y, Wang Q. Zein-based micro- and nano-particles for drug and nutrient delivery: a review. J Appl Polym Sci. 2014;131  https://doi.org/10.1002/app.40696.
  24. 24.
    S. Zhang, J. Ermann, M.D. Succi, A. Zhou, M.J. Hamilton, B. Cao, J.R. Korzenik, J.N. Glickman, P.K. Vemula, L.H. Glimcher, G. Traverso, R. Langer, J.M. Karp, An inflammation-targeting hydrogel for local drug delivery in inflammatory bowel disease, Sci Transl Med 7 (2015) 300ra128-300ra128. doi: https://doi.org/10.1126/scitranslmed.aaa5657.
  25. 25.
    Toma H. Injectable and biodegradable hydrogels: gelation, biodegradation and biomedical applications. Chem Soc Rev. 2012:2193–221.  https://doi.org/10.1039/c1cs15203c.
  26. 26.
    Shi J, Xing MMQ, Zhong W. Development of hydrogels and biomimetic regulators as tissue engineering scaffolds. Membranes (Basel). 2012;2:70–90.  https://doi.org/10.3390/membranes2010070.CrossRefGoogle Scholar
  27. 27.
    Hoare TR, Kohane DS. Hydrogels in drug delivery: progress and challenges. Polymer (Guildf). 2008;49:1993–2007.  https://doi.org/10.1016/j.polymer.2008.01.027.CrossRefGoogle Scholar
  28. 28.
    Sohail M, Ahmad M, Usman M, Ali L. Controlled delivery of valsartan by cross-linked polymeric matrices: synthesis, in vitro and in vivo evaluation. Int J Pharm. 2015;487:110–9.  https://doi.org/10.1016/j.ijpharm.2015.04.013.CrossRefPubMedGoogle Scholar
  29. 29.
    Jiang J, Parker CE, Fuller JR, Kawula TH, Borchers CH. NIH public access. Anal Chim Acta. 2008;605:70–9.  https://doi.org/10.1016/j.immuni.2010.12.017.Two-stage.CrossRefGoogle Scholar
  30. 30.
    Li J, Mooney DJ. Designing hydrogels for controlled drug delivery. Nat Publ Gr. 2016;1:1–18.  https://doi.org/10.1038/natrevmats.2016.71.Google Scholar
  31. 31.
    Long Zhao HM, Yosh F. Synthesis of pH-sensitive and biodegradable CM-cellulose/chitosan polyampholytic hydrogels with electron beam irradiation. J Bioact Compat Polym. 2008;23:319–33.  https://doi.org/10.1177/0883911508092302.CrossRefGoogle Scholar
  32. 32.
    Caló E, Khutoryanskiy VV. Biomedical applications of hydrogels: a review of patents and commercial products. Eur Polym J. 2015;65:252–67.  https://doi.org/10.1016/j.eurpolymj.2014.11.024.CrossRefGoogle Scholar
  33. 33.
    Neufeld L, Bianco-Peled H. Accepted crtInt J Biol Macromol. 2017;101:852–61.  https://doi.org/10.1016/j.ijbiomac.2017.03.167.CrossRefPubMedGoogle Scholar
  34. 34.
    Rehmani S, Ahmad M, Usman M, Hina M. Development of natural and synthetic polymer-based semi-interpenetrating polymer network for controlled drug delivery: optimization and in vitro evaluation studies. Polym Bull. 2016;74:737–61.  https://doi.org/10.1007/s00289-016-1743-y.CrossRefGoogle Scholar
  35. 35.
    Bhattarai N, Gunn J, Zhang M. Chitosan-based hydrogels for controlled, localized drug delivery. Adv Drug Deliv Rev. 2010;62:83–99.  https://doi.org/10.1016/j.addr.2009.07.019.CrossRefPubMedGoogle Scholar
  36. 36.
    Langer R, Vacanti J. Tissue engineering. Am. Assoc. Adv Sci. 1993;260:920–6.  https://doi.org/10.1016/j.biomaterials.2009.08.058.Thermosensitive.Google Scholar
  37. 37.
    Gumera C, Rauck B, Wang Y. Materials for central nervous system regeneration: bioactive cues. J Mater Chem. 2011;21:7033.  https://doi.org/10.1039/c0jm04335d.CrossRefGoogle Scholar
  38. 38.
    Sakai S, Hirose K, Taguchi K, Ogushi Y, Kawakami K. An injectable, in situ enzymatically gellable, gelatin derivative for drug delivery and tissue engineering. Biomaterials. 2009;30:3371–7.  https://doi.org/10.1016/j.biomaterials.2009.03.030.CrossRefPubMedGoogle Scholar
  39. 39.
    Tae G, Kim YJ, Il Choi W, Kim M, Stayton PS, Hoffman AS. Formation of a novel heparin-based hydrogel in the presence of heparin-binding biomolecules. Biomacromolecules. 2007;8:1979–86.  https://doi.org/10.1021/bm0701189.CrossRefPubMedGoogle Scholar
  40. 40.
    Lü S, Li B, Ni B, Sun Z, Liu M, Wang Q. Thermoresponsive injectable hydrogel for three-dimensional cell culture: chondroitin sulfate bioconjugated with poly(N-isopropylacrylamide) synthesized by RAFT polymerization. Soft Matter. 2011;7:10763.  https://doi.org/10.1039/c1sm06053h.CrossRefGoogle Scholar
  41. 41.
    Zhu J. Bioactive modification of poly(ethylene glycol) hydrogels for tissue engineering. Biomaterials. 2010;31:4639–56.  https://doi.org/10.1016/j.biomaterials.2010.02.044.Bioactive.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Buwalda SJ, Boere KWM, Dijkstra PJ, Feijen J, Vermonden T, Hennink WE. Hydrogels in a historical perspective: from simple networks to smart materials. J Control Release. 2014;190:254–73.  https://doi.org/10.1016/j.jconrel.2014.03.052.CrossRefPubMedGoogle Scholar
  43. 43.
    Lohani A, Singh G, Bhattacharya SS, Verma A. Interpenetrating polymer networks as innovative drug delivery systems. J Drug Deliv. 2014;2014:583612–1.  https://doi.org/10.1155/2014/583612.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Chatterjee B, Amalina N, Sengupta P, Mandal UK. Mucoadhesive polymers and their mode of action: a recent update, vol. 7; 2017. p. 195–203.  https://doi.org/10.7324/JAPS.2017.70533.Google Scholar
  45. 45.
    Dheer D, Arora D, Jaglan S, Rawal RK, Shankar R, Dheer D, et al. Polysaccharides based nanomaterials for targeted anti-cancer drug delivery, vol. 2330; 2017.  https://doi.org/10.3109/1061186X.2016.1172589.Google Scholar
  46. 46.
    An B, Lin YS, Brodsky B. Collagen interactions: drug design and delivery. Adv Drug Deliv Rev. 2016;97:69–84.  https://doi.org/10.1016/j.addr.2015.11.013.CrossRefPubMedGoogle Scholar
  47. 47.
    Ahmad E, Fatima MT, Hoque M, Owais M, Saleemuddin M. Fibrin matrices: the versatile therapeutic delivery systems. Int J Biol Macromol. 2015;81:121–36.  https://doi.org/10.1016/j.ijbiomac.2015.07.054.CrossRefPubMedGoogle Scholar
  48. 48.
    Van Tomme SR, Hennink WE. Biodegradable dextran hydrogels for protein delivery applications. Expert Rev Med Devices. 2007;4:147–64.  https://doi.org/10.1586/17434440.4.2.147.CrossRefPubMedGoogle Scholar
  49. 49.
    Kolanthai E, Ganesan K, Epple M, Kalkura SN. Synthesis of nanosized hydroxyapatite/agarose powders for bone filler and drug delivery application. Mater Today Commun. 2016;8:31–40.  https://doi.org/10.1016/j.mtcomm.2016.03.008.CrossRefGoogle Scholar
  50. 50.
    Mart RJ, Osborne RD, Stevens MM, Ulijn RV. Peptide-based stimuli-responsive biomaterials. Soft Matter. 2006;2:822.  https://doi.org/10.1039/b607706d.CrossRefGoogle Scholar
  51. 51.
    MacLeod GS, Fell JT, Collett JH. Studies on the physical properties of mixed pectin/ethylcellulose films intended for colonic drug delivery. Int J Pharm. 1997;157:53–60.  https://doi.org/10.1016/S0378-5173(97)00216-0.CrossRefGoogle Scholar
  52. 52.
    Semdé R, Amighi K, Pierre D, Devleeschouwer MJ, Moës AJ. Leaching of pectin from mixed pectin/insoluble polymer films intended for colonic drug delivery. Int J Pharm. 1998;174:233–41.  https://doi.org/10.1016/S0378-5173(98)00269-5.CrossRefGoogle Scholar
  53. 53.
    Wong TW, Nurjaya S. Drug release property of chitosan-pectinate beads and its changes under the influence of microwave. Eur J Pharm Biopharm. 2008;69:176–88.  https://doi.org/10.1016/j.ejpb.2007.09.015.CrossRefPubMedGoogle Scholar
  54. 54.
    Thakur BR, Singh RK, Handa AK, Rao MA. Critical reviews in food science and nutrition chemistry and uses of pectin—a review chemistry and uses of pectin—a review. Crit Rev Food Sci Nutr. 2009;37(1):47–73.  https://doi.org/10.1080/10408399709527767. CrossRefGoogle Scholar
  55. 55.
    Bawa P, Choonara YE, Du Toit LC, Kumar P, Ndesendo VMK, Meyer LCR, et al. A novel stimuli-synchronized alloy-treated matrix for space-defined gastrointestinal delivery of mesalamine in the large white pig model. J Control Release. 2013;166:234–45.  https://doi.org/10.1016/j.jconrel.2012.12.011.CrossRefPubMedGoogle Scholar
  56. 56.
    Bigucci F, Luppi B, Monaco L, Cerchiara T, Zecchi V. Pectin-based microspheres for colon-specific delivery of vancomycin. J Pharm Pharmacol. 2009;61:41–6.  https://doi.org/10.1211/jpp/61.01.0006.CrossRefPubMedGoogle Scholar
  57. 57.
    Eswaramma S, Reddy NS, Rao KSVK. Phosphate crosslinked pectin based dual responsive hydrogel networks and nanocomposites: development, swelling dynamics and drug release characteristics. Int J Biol Macromol. 2017;103:1162–72.  https://doi.org/10.1016/j.ijbiomac.2017.05.160.CrossRefPubMedGoogle Scholar
  58. 58.
    Almeida EAMS, Bellettini IC, Garcia FP, Farinácio MT, Nakamura CV, Rubira AF, et al. Curcumin-loaded dual pH- and thermo-responsive magnetic microcarriers based on pectin maleate for drug delivery. Carbohydr Polym. 2017;171:259–66.  https://doi.org/10.1016/j.carbpol.2017.05.034.CrossRefPubMedGoogle Scholar
  59. 59.
    R.K. Mishra, M. Datt, A.K. Banthia, Synthesis and characterization of pectin/PVP hydrogel membranes for drug delivery system, 9 (2008). doi: https://doi.org/10.1208/s12249-008-9048-6.
  60. 60.
    L. Costas, L.M. Pera, A.G. López, M. Mechetti, G.R. Castro, Controlled release of sulfasalazine release from “smart” pectin gel microspheres under physiological simulated fluids, (2012) 1396–1407. doi: https://doi.org/10.1007/s12010-012-9615-x.
  61. 61.
    Newton AMJ, Lakshmanan P. Effect of HPMC-E15 LV premium polymer on release profile and compression characteristics of chitosan/ pectin colon targeted mesalamine matrix tablets and in vitro study on effect of pH impact on the drug release profile. Recent Pat Drug Deliv Formul. 2014;8:46–62.  https://doi.org/10.2174/1872211308666140225143926.CrossRefPubMedGoogle Scholar
  62. 62.
    Birch NP, Barney LE, Pandres E, Peyton SR, JD. Thermal-responsive behavior of a cell compatible chitosan/pectin hydrogel Schiffman. Biomacromolecules. 2015;16(6);1837–1843Google Scholar
  63. 63.
    Ekaterina D, Sergey AM. Pectin-silica gels as matrices for controlled drug release in gastrointestinal tract. Carbohydr Polym. 2016;157:9–20.  https://doi.org/10.1016/j.carbpol.2016.09.048.Google Scholar
  64. 64.
    Kumar MNVR, Muzzarelli RAA, Muzzarelli C, Sashiwa H, Domb AJ. Chitosan chemistry and pharmaceutical perspectives. Chem Rev. 2004;104:6017–84.  https://doi.org/10.1021/cr030441b.CrossRefPubMedGoogle Scholar
  65. 65.
    J.J. Thevarajah, Characterisation of chitosan and its films, (2016).Google Scholar
  66. 66.
    Aider M. Chitosan application for active bio-based films production and potential in the food industry: review. LWT - Food Sci Technol. 2010;43:837–42.  https://doi.org/10.1016/j.lwt.2010.01.021.CrossRefGoogle Scholar
  67. 67.
    Muzzarelli RAA. Human enzymatic activities related to the therapeutic administration of chitin derivatives. Cell Mol Life Sci. 1997;53:131–40.  https://doi.org/10.1007/PL00000584.CrossRefPubMedGoogle Scholar
  68. 68.
    No HK, Young Park N, Ho Lee S, Meyers SP. Antibacterial activity of chitosans and chitosan oligomers with different molecular weights. Int J Food Microbiol. 2002;74:65–72.  https://doi.org/10.1016/S0168-1605(01)00717-6.CrossRefPubMedGoogle Scholar
  69. 69.
    Ravi Kumar MN. A review of chitin and chitosan applications. React Funct Polym. 2000;46:1–27.  https://doi.org/10.1016/S1381-5148(00)00038-9.CrossRefGoogle Scholar
  70. 70.
    Borchard G, Lueßen HL, De Boer AG, Verhoef JC, Lehr CM, Junginger HE. The potential of mucoadhesive polymers in enhancing intestinal peptide drug absorption. III: Effects of chitosan-glutamate and carbomer on epithelial tight junctions in vitro. J Control Release. 1996;39:131–8.  https://doi.org/10.1016/0168-3659(95)00146-8.CrossRefGoogle Scholar
  71. 71.
    S.T. Lim, B. Forbes, G.P. Martin, M.B. Brown, In vivo and in vitro characterization of novel microparticulates based on hyaluronan and chitosan hydroglutamate, 2 (2001).Google Scholar
  72. 72.
    Aguzzi C, Ortega A, Bonferoni MC, Sandri G, Cerezo P, Salcedo I, et al. Assessement of anti-inflammatory properties of microspheres prepared with chitosan and 5-amino salicylic acid over inflamed Caco-2 cells. Carbohydr Polym. 2011;85:638–44.  https://doi.org/10.1016/j.carbpol.2011.03.027.CrossRefGoogle Scholar
  73. 73.
    Qiu Y, Park K. Environment-sensitive hydrogels for drug delivery. Adv Drug Deliv Rev. 2012;64:49–60.  https://doi.org/10.1016/j.addr.2012.09.024.CrossRefGoogle Scholar
  74. 74.
    Bukhari SMH, Khan S, Rehanullah M, Ranjha NM. Synthesis and characterization of chemically cross-linked acrylic acid/gelatin hydrogels: effect of pH and composition on swelling and drug release. Int J Polym Sci. 2015;2015:1–15.  https://doi.org/10.1155/2015/187961.CrossRefGoogle Scholar
  75. 75.
    Duan H, Lu S, Qin H, Gao C, Bai X, Wei Y, et al. Co-delivery of zinc and 5-aminosalicylic acid from alginate/N-succinyl-chitosan blend microspheres for synergistic therapy of colitis. Int J Pharm. 2017;516:214–24.  https://doi.org/10.1016/j.ijpharm.2016.11.036.CrossRefPubMedGoogle Scholar
  76. 76.
    Wang QS, Wang GF, Zhou J, Gao LN, Cui YL. Colon targeted oral drug delivery system based on alginate-chitosan microspheres loaded with icariin in the treatment of ulcerative colitis. Int J Pharm. 2016;515:176–85.  https://doi.org/10.1016/j.ijpharm.2016.10.002.CrossRefPubMedGoogle Scholar
  77. 77.
    Ramadass SK, Perumal S, Jabaris SL, Madhan B. Preparation and evaluation of mesalamine collagen in situ rectal gel: a novel therapeutic approach for treating ulcerative colitis. Eur J Pharm Sci. 2013;48:104–10.  https://doi.org/10.1016/j.ejps.2012.10.015.CrossRefPubMedGoogle Scholar
  78. 78.
    Jr SBA, Nettles DL, Ph D, Setton LA. Author manuscript. J Biomed Mater Res Part B Appl Biomater. 2010:1–14.  https://doi.org/10.1002/jbm.b.31289.Release.
  79. 79.
    Mura C, Nácher A, Merino V, Merino-Sanjuan M, Carda C, Ruiz A, et al. N-Succinyl-chitosan systems for 5-aminosalicylic acid colon delivery: in vivo study with TNBS-induced colitis model in rats. Int J Pharm. 2011;416:145–54.  https://doi.org/10.1016/j.ijpharm.2011.06.025.PubMedGoogle Scholar
  80. 80.
    Bai XY, Yan Y, Wang L, Zhao LG, Wang K. Novel pH-sensitive hydrogels for 5-aminosalicylic acid colon targeting delivery: in vivo study with ulcerative colitis targeting therapy in mice. Drug Deliv. 2015;0:1–7.  https://doi.org/10.3109/10717544.2014.996924.CrossRefGoogle Scholar
  81. 81.
    Ju E, Park K, Su K, Kim J, Yang J, Kong J, et al. Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives. J Control Release. 2010;141:2–12.  https://doi.org/10.1016/j.jconrel.2009.09.010.CrossRefGoogle Scholar
  82. 82.
    Kim KS, Park SJ, Yang J, Jeon J, Bhang SH, Kim B, et al. Acta Biomaterialia injectable hyaluronic acid–tyramine hydrogels for the treatment of rheumatoid arthritis. Acta Biomater. 2011;7:666–74.  https://doi.org/10.1016/j.actbio.2010.09.030.CrossRefPubMedGoogle Scholar
  83. 83.
    J. Kim, I. Sook, T. Hyung, K. Back, S. Jung, G. Tae, I. Noh, S. Hoon, Y. Park, K. Sun, Bone regeneration using hyaluronic acid-based hydrogel with bone morphogenic protein-2 and human mesenchymal stem cells, 28 (2007) 1830–1837. doi: https://doi.org/10.1016/j.biomaterials.2006.11.050.
  84. 84.
    Jung HH, Park K, Han DK. Preparation of TGF-β 1-conjugated biodegradable pluronic F127 hydrogel and its application with adipose-derived stem cells. J Control Release. 2010;147:84–91.  https://doi.org/10.1016/j.jconrel.2010.06.020.CrossRefPubMedGoogle Scholar
  85. 85.
    Manuscript A, Cells S, Hyaluronic U, Crosslinked D. NIH public access, vol. 32; 2012. p. 2466–78.  https://doi.org/10.1016/j.biomaterials.2010.12.024.Controlling. Google Scholar
  86. 86.
    Xiao B, Zhang Z, Viennois E, Kang Y, Zhang M, Han MK. Combination therapy for ulcerative colitis: orally targeted nanoparticles prevent mucosal damage and relieve inflammation. Theranostics. 2016;6  https://doi.org/10.7150/thno.15710.
  87. 87.
    George M, Abraham TE. Polyionic hydrocolloids for the intestinal delivery of protein drugs: alginate and chitosan—a review. J Control Release. 2006;114:1–14.  https://doi.org/10.1016/j.jconrel.2006.04.017. CrossRefPubMedGoogle Scholar
  88. 88.
    Grellier M, Granja PL, Fricain JC, Bidarra SJ, Renard M, Bareille R, et al. The effect of the co-immobilization of human osteoprogenitors and endothelial cells within alginate microspheres on mineralization in a bone defect. Biomaterials. 2009;30:3271–8.  https://doi.org/10.1016/j.biomaterials.2009.02.033.CrossRefPubMedGoogle Scholar
  89. 89.
    K.M. Dupont, J.D. Boerckel, N. Huebsch, NIH public access, east 32 (2012) 65–74. doi: https://doi.org/10.1016/j.biomaterials.2010.08.074.An.
  90. 90.
    Yu J, Du KT, Fang Q, Gu Y, Mihardja SS, Sievers RE, et al. The use of human mesenchymal stem cells encapsulated in RGD modified alginate microspheres in the repair of myocardial infarction in the rat. Biomaterials. 2010;31:7012–20.  https://doi.org/10.1016/j.biomaterials.2010.05.078.CrossRefPubMedGoogle Scholar
  91. 91.
    Dawlee S, Sugandhi A, Balakrishnan B, Labarre D, Jayakrishnan A. Oxidized chondroitin sulfate-cross-linked gelatin matrixes: a new class of hydrogels. Biomacromolecules. 2005;6:2040–8.  https://doi.org/10.1021/bm050013a.CrossRefPubMedGoogle Scholar
  92. 92.
    Barkat K, Ahmad M, Minhas MU, Khalid I. Oxaliplatin-loaded crosslinked polymeric network of chondroitin sulfate-co-poly(methacrylic acid) for colorectal cancer: its toxicological evaluation. J Appl Polym Sci. 2017;45312:45312.  https://doi.org/10.1002/app.45312.CrossRefGoogle Scholar
  93. 93.
    You YC, Dong LY, Dong K, Xu W, Yan Y, Zhang L, et al. In vitro and in vivo application of pH-sensitive colon-targeting polysaccharide hydrogel used for ulcerative colitis therapy. Carbohydr Polym. 2015;130:243–53.  https://doi.org/10.1016/j.carbpol.2015.03.075.CrossRefPubMedGoogle Scholar
  94. 94.
    Birch NP, Birch NP, Barney LE, Pandres E, Peyton SR, Schi JD. Thermal-responsive behavior of a cell compatible chitosan/pectin hydrogel; 2015.  https://doi.org/10.1021/acs.biomac.5b00425.Google Scholar
  95. 95.
    Ondeck MG, Engler AJ. Mechanical characterization of a dynamic and tunable methacrylated hyaluronic acid hydrogel. J Biomech Eng. 2016;138:21003.  https://doi.org/10.1115/1.4032429.CrossRefGoogle Scholar
  96. 96.
    Hu J, Li HY, Williams GR, Yang HH, Tao L, Zhu LM. Electrospun poly(N-isopropylacrylamide)/ethyl cellulose nanofibers as thermoresponsive drug delivery systems. J Pharm Sci. 2016;105:1104–12.  https://doi.org/10.1016/S0022-3549(15)00191-4.CrossRefPubMedGoogle Scholar
  97. 97.
    Feng H, Zhang L, Zhu C. Genipin crosslinked ethyl cellulose-chitosan complex microspheres for anti-tuberculosis delivery. Colloids Surf B Biointerfaces. 2013;103:530–7.  https://doi.org/10.1016/j.colsurfb.2012.11.007.CrossRefPubMedGoogle Scholar
  98. 98.
    Kapoor DN, Bhatia A, Kaur R, Sharma R, Kaur G, Dhawan S. PLGA: a unique polymer for drug delivery. Ther Deliv. 2015;6:41–58.  https://doi.org/10.4155/tde.14.91.CrossRefPubMedGoogle Scholar
  99. 99.
    Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers (Basel). 2011;3:1377–97.  https://doi.org/10.3390/polym3031377.CrossRefGoogle Scholar
  100. 100.
    Ostroha JL, Lowman A, Dan N. PEG-based degradable networks for drug delivery applications. Chem Biol Eng Doctor of. 2006;165 http://hdl.handle.net/1860/842
  101. 101.
    Kolate A, Baradia D, Patil S, Vhora I, Kore G, Misra A. PEG—a versatile conjugating ligand for drugs and drug delivery systems. J Control Release. 2014;192:67–81.  https://doi.org/10.1016/j.jconrel.2014.06.046.CrossRefPubMedGoogle Scholar
  102. 102.
    Zhao L, Liu M, Wang J, Zhai G. Chondroitin sulfate-based nanocarriers for drug/gene delivery. Carbohydr Polym. 2015;133:391–9.  https://doi.org/10.1016/j.carbpol.2015.07.063.CrossRefPubMedGoogle Scholar
  103. 103.
    Ramasamy T, Khandasamy US, Shanmugam S, Ruttala H. Formulation and evaluation of chondroitin sulphate tablets of aceclofenac for colon targeted drug delivery, Iran. J Pharm Res. 2012;11:465–79.  https://doi.org/10.1590/S1984-82502011000200011.Google Scholar
  104. 104.
    Davaran S, Rashidi MR, Khani A. Synthesis of chemically cross-linked hydroxypropyl methyl cellulose hydrogels and their application in controlled release of 5-amino salicylic acid. Drug Dev Ind Pharm. 2007;33:881–7.  https://doi.org/10.1080/03639040601150278.CrossRefPubMedGoogle Scholar
  105. 105.
    Siepmann J, Peppas NA. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Deliv Rev. 2001;48:139–57.  https://doi.org/10.1016/S0169-409X(01)00112-0.CrossRefPubMedGoogle Scholar
  106. 106.
    Dasgupta A, Mondal JH, Das D. Peptide hydrogels. RSC Adv. 2013;3:9117–49.  https://doi.org/10.1039/c3ra40234g.CrossRefGoogle Scholar
  107. 107.
    Aytac Z, Sen HS, Durgun E, Uyar T. Sulfisoxazole/cyclodextrin inclusion complex incorporated in electrospun hydroxypropyl cellulose nanofibers as drug delivery system. Colloids Surf B Biointerfaces. 2015;128:331–8.  https://doi.org/10.1016/j.colsurfb.2015.02.019.CrossRefPubMedGoogle Scholar
  108. 108.
    S. Poh, J.B. Lin, A. Panitch, Release of anti-inflammatory peptides from thermosensitive nanoparticles with degradable cross-links suppresses pro-inflammatory cytokine production, (2015). doi: https://doi.org/10.1021/bm501849p.
  109. 109.
    Singh B, Sharma N, Chauhan N. Synthesis, characterization and swelling studies of pH responsive psyllium and methacrylamide based hydrogels for the use in colon specific drug delivery. Carbohydr Polym. 2007;69:631–43.  https://doi.org/10.1016/j.carbpol.2007.01.020.CrossRefGoogle Scholar
  110. 110.
    Bezzio C, Fascì-Spurio F, Viganò C, Meucci G, Papi C, Saibeni S. The problem of adherence to therapy in ulcerative colitis and the potential utility of multi-matrix system (MMX) technology. Expert Rev Gastroenterol Hepatol. 2017;11:33–41.  https://doi.org/10.1080/17474124.2017.1256200.CrossRefPubMedGoogle Scholar

Copyright information

© Controlled Release Society 2018

Authors and Affiliations

  • Muhammad Sohail
    • 1
  • Mudassir
    • 1
  • Muhammad Usman Minhas
    • 2
  • Shahzeb Khan
    • 3
  • Zahid Hussain
    • 4
  • Marcel de Matas
    • 5
  • Syed Ahmed Shah
    • 1
  • Samiullah Khan
    • 2
  • Mubeen Kousar
    • 1
  • Kaleem Ullah
    • 1
  1. 1.Department of PharmacyCOMSATS Institute of Information TechnologyAbbottabadPakistan
  2. 2.Faculty of Pharmacy and Alternative MedicineThe Islamia University of BahawalpurBahawalpurPakistan
  3. 3.Department of PharmacyUniversity of MalakandLower DirPakistan
  4. 4.Department of Pharmaceutics, Faculty of PharmacyUniversiti Teknologi MARA (UiTM)Bandar Puncak AlamMalaysia
  5. 5.SEDA Pharmaceutical Development ServicesCheshireUK

Personalised recommendations